Biocon Limited announced its consolidated financial results for the first quarter of FY27, ending June 30, 2026. Total income saw a 9% year-on-year increase to ₹4,391 crore. EBITDA stood at ₹902 crore. Notably, Net Profit before exceptional items surged by 245% to ₹145 crore, while Net Profit after exceptional items was ₹141 crore, a 355% rise from the previous year.
Biocon Reports Strong Q1 FY27 Financial Performance
Biocon Limited has unveiled its financial results for the fiscal first quarter ended June 30, 2026, highlighting robust growth across key financial metrics. The company’s consolidated total income reached ₹4,391 crore, marking a 9% increase compared to the same period last year. This growth was primarily driven by a strong performance in the Biopharma business.
Key Financial Highlights
The company reported a consolidated EBITDA of ₹902 crore, with a margin of 21%. A significant highlight was the Net Profit before exceptional items, which saw a substantial surge of 245% to ₹145 crore. The reported Net Profit for the period stood at ₹141 crore, representing an impressive 355% year-on-year growth.
Revenue Breakdown
Consolidated operating revenue increased by 10% YoY to ₹4,336 crore. The Biopharma segment showed remarkable growth, with revenue up 17% YoY, fueled by recent biosimilar and generic product launches. Biosimilars revenue grew by 16% to ₹2,855 crore, and Generics revenue saw a 21% increase to ₹760 crore. Conversely, Services revenue decreased by 16% to ₹736 crore due to ongoing market challenges.
Leadership Commentary
Kiran Mazumdar-Shaw, Executive Chairperson, stated, “Biocon has entered FY27 with a clear focus on translating our strategic investments into sustainable growth and long-term value creation.” Shreehas Tambe, CEO & Managing Director, added, “Biocon delivered a resilient performance in Q1FY27, reporting consolidated revenue from operations growth of 10% year-on-year to Rs 4,336 crore and EBITDA of Rs 902 crore.”
Operational Achievements
The press release also detailed several business performance updates. In North America, growth was driven by the ramp-up of biosimilars Bosaya™ and Aukelso™, with the commercialization of Yesafili™ and generic Liraglutide. In Europe, the company commercialized biosimilars Evfraxy® and Abevmy®. Biocon also secured regulatory approval for Yesafili™ in Malaysia.
Balance Sheet Strength
Interest costs were reduced by 23% YoY to ₹213 crore, reflecting actions taken to strengthen Biocon’s balance sheet. The company is preparing to host an Earnings Call on August 6, 2026, to discuss its performance and answer investor queries.
Source: BSE
